4.5 Article

All-Trans-Retinoic Acid Plus Oxaliplatin/Fluorouracil/Leucovorin for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis: A Multicenter Retrospective Study

期刊

CANCER MANAGEMENT AND RESEARCH
卷 14, 期 -, 页码 1663-1670

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/CMAR.S354170

关键词

hepatocellular carcinoma; pulmonary metastasis; chemotherapy; ATRA

类别

资金

  1. National Natural Science Foundation of China [82073293]
  2. Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center (Joint Project of Emerging Frontier Technology) [82073293]
  3. Key Project of Natural Science Foundation of China [81730097]

向作者/读者索取更多资源

The study aimed to compare the impact of All-trans-retinoic acid (ATRA) plus FOLFOX4 with FOLFOX4 alone on advanced hepatocellular carcinoma (HCC) patients with pulmonary metastasis. The results showed that ATRA plus FOLFOX4 significantly improved survival outcomes and had better overall survival rates compared to FOLFOX4 alone. The most common acute toxicities were leukocytopenia, fatigue, anorexia, and nausea, but there was no significant difference in adverse events between the two groups.
Aim: To study the impact of All-trans-retinoic acid (ATRA) plus FOLFOX4 compared to FOLFOX4 alone in patients with advanced hepatocellular carcinoma (HCC) with pulmonary metastasis. Methods: The data of patients with advanced HCC who underwent systemic chemotherapy using FOLFOX4 or ATRA plus FOLFOX4 at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University, Zhejiang Sian International Hospital and Fujian Cancer Hospital were retrospectively analyzed. The survival outcomes in the 2 groups were compared. Results: From May 2014 to July 2020, 66 patients were suitable to enter into this study. The median survival (14.0 vs 8.0 months, p=0.012), and the median time to progression in the ATRA plus FOLFOX4 group were both significantly longer than those in the FOLFOX4 group (8.7 vs 3.2 months, p=0.002). The 6 month-, 1 year- and 2 year- overall survival rates were also significantly better in the ATRA plus FOLFOX4 group (100.0%, 64.7% and 20.5%; respectively) than the FOLFOX4 group (59.4%, 21.9%, and 12.5%, respectively; p<0.001). Leukocytopenia, fatigue, anorexia, nausea, were the most common acute toxicities, but these were mostly NCI CTCAE Grade 1 or 2. There was no significant difference in adverse events between the two groups. Conclusion: ATRA plus FOLFOX4 significantly improved the survival outcomes in patients with advanced HCC with pulmonary metastasis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据